Amy J. Johnson

21.7k citations

191 papers · 9.3k indexed · 5 hit papers · h-index 49

Impact in

Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 145
- Chronic Lymphocytic Leukemia Research 145
Pathology and Forensic Medicine 62
- Lymphoma Diagnosis and Treatment 57

Co-authors: John C. Byrd Jennifer A. Woyach Kristie A. Blum Nyla A. Heerema Joseph M. Flynn Jeffrey A. Jones Leslie A. Andritsos Michael R. Grever
Journals: Blood (92 papers)Journal of Clinical Oncology (13 papers)Cancer Research (11 papers)Clinical Cancer Research (6 papers)Leukemia Research (4 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Amy J. Johnson

188 papers receiving 9.2k citations

Hit Papers

5 papers align trajectories log scale

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation 2018 · 298 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Biochemistry
2017 Journal of Clinical Investigation
2015 Blood
2011 Blood
2010 Blood

Peers

Countries citing papers authored by Amy J. Johnson

Since Specialization

Citations

This map shows the geographic impact of Amy J. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy J. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy J. Johnson more than expected).

Fields of papers citing papers by Amy J. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy J. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy J. Johnson. The network helps show where Amy J. Johnson may publish in the future.

Co-authors

The 25 scholars most cited alongside Amy J. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amy J. Johnson Line = papers co-authored together Amy J. Johnson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies Blood Cancer Discovery ·Christopher Melani, Max J. Gordon, M R. HAYDEN, Stefania Pittaluga, Li Chenmeng, Jagan Muppidi, James D. Phelan, Svetlana Pack, Amynah Pradhan, Candis Morrison, Rati Nofrianti, مریم آجورلو, Amy J. Johnson, Melanie M. Frigault, Ahmed Hamdy, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson	2024	0
2	Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma SHILAP Revista de lepidopterología ·Simone de Freitas sILVA, Makoto KANAMARU, Melanie M. Frigault, Beatrix Stelte‐Ludwig, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Ranjan Maity, Nizar J. Bahlis, Paola Neri, Aru Narendran	2024	1
3	British Association of Dermatologists living guideline for managing people with alopecia areata 2024 British Journal of Dermatology ·Matthew Harries, Anna Ascott, Leila Asfour, Paul Farrant, Maria Gousiopoulou, Sveva Grigioni Baur, Amy J. Johnson, Victoria Jolliffe, 魏晓月, A. E. Macbeth, Andrew G. Messenger, J-F Pinton, Anita Takwale, Andrew R. Thompson, Maria Hashme, L. Manounah, M.F. Mohd Mustapa, 石橋昌也	2024	9
4	Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription Cancer Research Communications ·Melanie M. Frigault, Stavros Giagkousiklidis, Harvey Wong, Beatrix Stelte‐Ludwig, JHHW, 鄂冠中, Joseph Birkett, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy	2023	7
5	Discovery of VIP236, an αvβ3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors Cancers ·Hans‐Georg Lerchen, Beatrix Stelte‐Ludwig, Mélanie Héroult, WU Li-qi, Kersten M. Gericke, Harvey Wong, Melanie M. Frigault, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy	2023	8
6	Patients' Experiences of Primary Healthcare and Dermatology Provision for Alopecia SHILAP Revista de lepidopterología ·Fabio Zucchelli, Marije van Dalen, yumei Fan, Amy J. Johnson, Lekshmi Padmanabhanan	2023	1
7	Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a systematic review of alopecia areata clinical practice guidelines Clinical and Experimental Dermatology ·Leila Asfour, Przemysław Szews, Ali Al‐Janabi, Dorith Michaeli, Amy J. Johnson, Carsten Flohr, Zenas Z N Yiu	2022	6
8	Modulation of immune checkpoint molecule expression in mantle cell lymphoma Leukemia & lymphoma ·Bonnie K. Harrington, Esther F. Wheeler, 砂川恵, Alberto Pecorini, Youssef Youssef, Lisa Smith, W.A.R Wan Eny Zarina, Brett Klamer, Xiaoli Zhang, Meixiao Long, Robert A. Baiocchi, Kami J. Maddocks, Amy J. Johnson, John C. Byrd, Lapo Alinari	2019	23
9	Development of the Bonding with Dog Checklist (BoDC) A.C.S. Silva, Annmarie Caño, Rita J. Casey, Amy J. Johnson, M.T. Bozzi, Lee H. Wurm	2018	1
10	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Cancer Research ·Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Елена Александровна Леонова, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien	2017	47
11	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia Clinical Cancer Research ·Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger G. Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach	2016	121
12	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia Blood ·Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, 조인제, Lisa L. Smith, Katie Williams, Amy J. Johnson, Amy M. Lehman, John C. Byrd, Jennifer A. Woyach, Rosa Lapalombella	2015	72
13	Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma Cancer Discovery ·David Chiron, Maurizio Di Liberto, Peter Martin, Xiangao Huang, Jeff P. Sharman, Pedro Blecua, Susan Mathew, Priyanka Vijay, Ken Eng, Siraj M. Ali, Amy J. Johnson, Betty Chang, Scott Ely, Olivier Elemento, Christopher E. Mason, John P. Leonard, Selina Chen‐Kiang	2014	204
14	A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol Clinical Cancer Research ·Jia Ji, Diane R. Mould, Kristie A. Blum, Amy S. Ruppert, Ming Poi, Yuan Zhao, Amy J. Johnson, John C. Byrd, Michael R. Grever, Mitch A. Phelps	2013	19
15	Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol Autophagy ·Emilia Mahoney, John C. Byrd, Amy J. Johnson	2013	35
16	Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol Leukemia ·Kristie A. Blum, Zahra Akbary, Jennifer A. Woyach, Jeffrey A. Jones, Leslie A. Andritsos, Joseph M. Flynn, Brad H. Rovin, Miguel A. Villalona‐Calero, JI Jun-sheng, Mitch A. Phelps, Amy J. Johnson, Michael R. Grever, John C. Byrd	2011	36
17	Epigenetic alterations in a murine model for chronic lymphocytic leukemia Cell Cycle ·Shih-Shih Chen, Mara H. Sherman, Erin Hertlein, Amy J. Johnson, Michael A. Teitell, John C. Byrd, Christoph Plass	2009	21
18	Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia Journal of Clinical Oncology ·Leslie A. Andritsos, Amy J. Johnson, Gerard Lozanski, William Blum, Cheryl Kefauver, Farrukh T. Awan, Lisa L. Smith, Rosa Lapalombella, Sarah May, Chelsey A. Raymond, Da-Sheng Wang, Robert Knight, Amy S. Ruppert, Amy Lehman, David Jarjoura, Ching-Shih Chen, John C. Byrd	2008	117
19	Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia British Journal of Haematology ·Amy J. Johnson, Amy J. Wagner, Carolyn Cheney, Lisa L. Smith, David Lucas, Thomas Carpenito, Michael R. Grever, Thomas S. Lin, John C. Byrd	2007	18
20	Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanism(s) of action Cancer Research ·Amy J. Johnson, David Lucas, Lisa L. Smith, Zhou Jundon, Thomas S. Lin, Michael R. Grever, John C. Byrd	2005	4

About Amy J. Johnson

Amy J. Johnson is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Immunology and Oncology, having authored 191 papers that have together received 9.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (145 papers), Lymphoma Diagnosis and Treatment (57 papers), Advanced Breast Cancer Therapies (27 papers), Immunodeficiency and Autoimmune Disorders (25 papers), PI3K/AKT/mTOR signaling in cancer (21 papers), Chronic Myeloid Leukemia Treatments (19 papers), Acute Lymphoblastic Leukemia research (15 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). The work is most often cited by research in Genetics (5.7k citations), Pathology and Forensic Medicine (4.0k citations), Hematology (1.9k citations), Immunology (2.6k citations) and Oncology (2.2k citations). Amy J. Johnson has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include John C. Byrd, Jennifer A. Woyach, Kristie A. Blum, Nyla A. Heerema, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Michael R. Grever, Sarah E.M. Herman and Amber Gordon. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact